Introduction of SDT Fatty Rat Diabetic Nephropathy Model.

2023/11/17

Introduction of SDT Fatty Rat Diabetic Nephropathy Model.

▼ Inquiry here

In diabetes research, there has been a need for rat models that develop diabetes earlier.

SDT fatty rats were created in 2004 by introducing a leptin receptor mutation into the 1-type diabetes model SDT rats.

SDT fatty rats develop diabetes much earlier than SDT rats, with blood glucose levels reaching 600mg/dl at 8 weeks of age, allowing for early testing.

CLEA Japan has been selling SDT fatty rats, a model of type 2 diabetes, since 2012.

Several research papers have been published since then to demonstrate the validity of this model.

→However, it was not yet recognized as a globally established model.

4 years later…

In 2016, Physiogenex, a CRO in France, approached us to become a representative for their NASH contract research service in Japan.

Physiogenex is a leading CRO in diabetes, particularly NASH and heart failure, and provides services to major pharmaceutical companies.

The agency contract was progressing, and then it happened during a break.

CLEA Japan Sales Executive (Executive):

“Do you know SDT fatty rats? Would you like to develop it as a NASH model? We can provide the animals for free.”

Dr. Briand:

“Currently, we have good NASH animal models. But... One of my client is looking for an animal that can develop kidney disease due to diabetes within 25 weeks. We can confirm if SDT fatty rats can develop nephropathy by diabetic symptoms.”

Then, we confirmed three conditions of the model development.

To achieve these, we had to add more methods to induce diabetic nephropathy.

Strain on the kidneys: ・Addition of 0.3% table salt to drinking water ・Unilateral nephrectomy

Result

Result: Blood glucose levels remained significantly elevated after unilateral nephrectomy and salt supplement, despite GFR being reduced to less than half.

Result: Pathological analysis also showed renal dysfunctions.

"The results were better than expected! This should be good for our customers. I would like to move on to the next step." “We would like to do drug evaluations! The candidate compounds are SGLT2 inhibitors (dapagliflozin) and ACE inhibitors (ramipril).”